Effect of Natalizumab on Disease Progression in Secondary Progressive Multiple Sclerosis (ASCEND): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial With an Open-Label Extension

The Lancet Neurology - United Kingdom
doi 10.1016/s1474-4422(18)30069-3
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Elsevier BV


Related search